Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics Signs Three-Year, $2.4M Renewal of Protein Interaction Services Deal


French biotech firm Hybrigenics said this week that it has renewed a three-year, $2.4 million research services agreement with an unnamed US life sciences company.

Under the agreement, Hybrigenics will continue to offer its two-hybrid screens and build databases of protein interactions identified through these screens.

The new deal follows an initial three-year agreement that began in 2009. Under the new terms, the annual fee due Hybrigenics has increased from $700,000 to $790,000.

Hybrigenics has an R&D program aimed at developing treatments for diseases including prostate cancer and psoriasis, but the bulk of its revenues come from its fee-for-service protein interaction work, which is housed within its Hybrigenics Services component — a fully owned subsidiary the company created in July 2010. In the first half of 2012, its protein interaction services generated €1.4 million ($1.8 million) of the firm's total €2 million in revenues.

Clients for these services include firms like Pfizer, GlaxoSmithKline, and L'Oreal, as well as academic customers like Harvard and Johns Hopkins University.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.